Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: The alfa-9802 study

Blood

Volumn 118, Issue 7, 2011, Pages 1754-1762

  Thomas, Xavier ^a   Elhamri, Mohamed ^a   Raffoux, Emmanuel ^b   Renneville, Aline ^c   Pautas, Cécile ^d   De Botton, Stéphane ^e   De Revel, Thierry ^f   Reman, Oumedaly ^g   Terré, Christine ^h   Gardin, Claude ⁱ   Chelghoum, Youcef ^a   Boissel, Nicolas ^b   Quesnel, Bruno ^c   Hicheri, Yosr ^d   Bourhis, Jean Henri ^e   Fenaux, Pierre ⁱ   Preudhomme, Claude ^c   Michallet, Mauricette ^a   Castaigne, Sylvie ^h   Dombret, Hervé ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PERCY MILITARY HOSPITAL   (France)

^g Centre de Gerontologie Georges CLEMENCEAU   (France)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE SEQUENCE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEVER; FRANCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEAMTOLOGIC DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TIMED SEQUENTIAL CANCER CHEMOTHERAPY; TREATMENT OUTCOME;

EID: 80051877778     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349258     Document Type: Article

References (35)

1. Castaigne S., Chevret S., Archimbaud E., et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467-2474. (Pubitemid 39331849)
2. Mayer R.J., Davies R.B., Schiffer C.A., et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903. (Pubitemid 24299870)
3. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173-4179. (Pubitemid 28440576)
4. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767-3775.
5. Byrd J.C., Ruppert A.S., Mrozek K., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-1094. (Pubitemid 41095042)
6. Farag S.S., Ruppert A.S., Mrozek K., et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukelia Group B study. J Clin Oncol. 2005;23(3):482-493. (Pubitemid 46224225)
7. World Health Organization. World Health Organization Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979:48:1-45.
8. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):626-629.
9. Bennett J.M., Catovsky D., Daniel M.T., et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): A report from the French-American-British Cooperative Group. Ann Intern Med. 1985;103(3):460-462. (Pubitemid 15236588)
10. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78(4):325-329.
11. Thomas X., Raffoux E., Botton S., et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453-461.
12. Cheson B.D., Cassileth P.A., Head D.R., et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
13. International System for Human Cytogenetic Nomenclature. Guidelines for cancer cytogenetics. In: Mitelman F, ed. Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1991:11-53.
14. Thomas X., Raffoux E., Renneville A., et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer. 2010;116(7):1725-1732.
15. Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood. 1996;88(8):2841-2851. (Pubitemid 26357364)
16. Löwenberg B., Griffin J.D., Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003;82-101.
17. Estey E., Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907. (Pubitemid 44794525)
18. Miyawaki S., Ohtake S., Fujisawa S., et al. A randomized comparison of four courses of standard-dose multiagent chemotherapy versus three courses of high-dose cytarabine alone in post-remission therapy for acute myeloid leukemia in adults: The JALSG AML201 study. Blood. 2011;117(8):2366-2372.
19. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
20. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
21. Renneville A., Boissel N., Gachard N., et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood. 2009;113(21):5090-5093.
22. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
23. Schlenk R.F., Pasquini M.C., Perez W.S., et al. HLAidentical sibling in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transpl. 2008;14(2):187-196.
24. Cornelissen J.J., Van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood. 2007; 109(9):3658-3666. (Pubitemid 46641712)
25. Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A meta-analysis. Cancer. 2005;103(8):1652-1658. (Pubitemid 40490026)
26. Nguyen S., Leblanc T., Fenaux P., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood. 2002;99(10):3517-3523. (Pubitemid 34534517)
27. Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462-469. (Pubitemid 36841961)
28. Neubauer A., Maharry K., Mrozek K., et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4603-4609.
29. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96(13):4075-4083.
30. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1): 409-417. (Pubitemid 47026863)
31. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
32. Elonen E., Almqvist A., Hänninen A., et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: A randomized trial of the Finnish Leukemia Group. Leukemia. 1998;12(7):1041-1048. (Pubitemid 28349798)
33. Burnett A.K., Goldstone A.H., Stevens R.M.F., et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet. 1998;351(9104):700-708. (Pubitemid 28105339)
34. Moore J.O., George S.L., Dodge R.K., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as post-remission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105(9): 3420-3427. (Pubitemid 40628181)
35. Thomas X., Raffoux E., Elhamri M., Lobe I., Cannas G., Dombret H. Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncol. 2009;5(8):1197-1210.